269 related articles for article (PubMed ID: 24892627)
1. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
[TBL] [Abstract][Full Text] [Related]
2. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
4. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
5. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
7. PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer.
Ye Y; Zhang L; Dai Y; Wang Z; Li C; Peng Y; Ma D; He P
Int J Nanomedicine; 2020; 15():7173-7184. PubMed ID: 33061374
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.
Taghdisi SM; Danesh NM; Sarreshtehdar Emrani A; Tabrizian K; Zandkarimi M; Ramezani M; Abnous K
J Drug Target; 2013 Sep; 21(8):739-44. PubMed ID: 23815443
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy.
Chen Z; Tai Z; Gu F; Hu C; Zhu Q; Gao S
Eur J Pharm Biopharm; 2016 Oct; 107():130-41. PubMed ID: 27393562
[TBL] [Abstract][Full Text] [Related]
10. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
11. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.
Takeshita F; Minakuchi Y; Nagahara S; Honma K; Sasaki H; Hirai K; Teratani T; Namatame N; Yamamoto Y; Hanai K; Kato T; Sano A; Ochiya T
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12177-82. PubMed ID: 16091473
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S
Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging and treatment of PSMA-positive prostate cancer with
Jiao Y; Xu P; Luan S; Wang X; Gao Y; Zhao C; Fu P
Nucl Med Biol; 2022; 104-105():28-37. PubMed ID: 34847481
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
16.
Nonnekens J; Chatalic KL; Molkenboer-Kuenen JD; Beerens CE; Bruchertseifer F; Morgenstern A; Veldhoven-Zweistra J; Schottelius M; Wester HJ; van Gent DC; van Weerden WM; Boerman OC; de Jong M; Heskamp S
Cancer Biother Radiopharm; 2017 Mar; 32(2):67-73. PubMed ID: 28301262
[TBL] [Abstract][Full Text] [Related]
17. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
[TBL] [Abstract][Full Text] [Related]
18. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-modified PLGA nanoparticle delivery of triplex forming oligonucleotide for targeted prostate cancer therapy.
Jiao J; Zou Q; Zou MH; Guo RM; Zhu S; Zhang Y
Neoplasma; 2016; 63(4):569-75. PubMed ID: 27268920
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
